Blood Phoenixin-14 Levels and Echocardiographic Findings in Infants of Diabetic Mothers

Launched by KONYA CITY HOSPITAL · Mar 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how certain heart-related problems in newborns of mothers with diabetes might be linked to high levels of a substance called phoenixin-14 in their blood. The researchers want to understand if these elevated levels could help identify heart issues earlier in these infants. The study is currently recruiting participants, and it’s open to healthy term infants aged 1 to 5 who were born to mothers with diabetes.

To be eligible for the trial, infants must be healthy and born at full term (around 37 to 42 weeks of pregnancy). However, infants whose families do not give consent or who have heart defects or certain genetic conditions cannot participate. If your child is eligible and joins the study, they will likely undergo some tests, including heart scans, to help the researchers gather important information. This study aims to improve our understanding of how diabetes in mothers can affect their babies' heart health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Infants of diabetic mothers
• • Healthy term infants
• Exclusion Criteria:
• • Infants whose families did not provide consent
• • Infants with a syndromic appearance or congenital heart disease